I have to agree with you. That's RGS's best presentation in 2 years. Clear, timeframed, and above all exciting. One can see the critical role that Dr Blaber (who just re-joined RGS) is going to have as Clinical Director.
This presentation makes think RGS has finally moved from R&D company only, then R&D + partnership (Kyocera) to finally a clinical biotech which has the financial resources to back their claims and discoveries.
Impressive
RGS Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
